PRS4 Economic Evaluation of the Use of Palivizumab as prophylactic Treatment for the reduction of Complications associated with respiratory Syncytial Virus in Pre-Term Patients
Abstract
Authors
E. Mayen-Herrera K. Buesch D. Cortina